Blocking $600 Million in Global Vaccine Funding Is a Grave Misstep

I was born in Cameroon in the 1980s. Like millions of children in similar settings, survival into adulthood was not guaranteed. But the launch of Gavi at the turn of the century had a measurable effect on reducing child mortality across dozens of low-income countries. Over the last two decades, Gavi has supported the immunization of 1.2 billion children and prevented more than 20 million deaths through its work to address the persistent structural inequity in access to vaccines.

That progress is now at risk. Last week, HHS blocked $600 million in congressionally appropriated funding for Gavi, the Vaccine Alliance. This is not just another marginal policy dispute but a decision that risks undermining one of the most effective global mechanisms for preventing infectious disease and, by extension, protecting U.S. public health.

For a small fraction of the U.S. health budget, Gavi functions as a first line of defense against outbreaks that do not respect borders. Vaccination gaps abroad do not remain local. They increase the risk of virus importation, raise the cost of outbreak control, and ultimately place greater strain on domestic health systems. Weakening this infrastructure shifts risk upstream, where it is harder and more expensive to contain.

HHS’s stated justification for withholding funds is that Gavi has failed to provide sufficient transparency around how U.S. dollars are used. The agency also expressed renewed concerns about thimerosal-containing vaccines. Both claims collapse under scrutiny.

Gavi is one of the most heavily audited and performance-tracked global health institutions. Its financing, procurement, and delivery mechanisms are publicly reported and subject to multilateral oversight. If there are specific deficiencies, they should be articulated and addressed directly. Broad, non-specific claims of opacity without evidence simply do not meet the threshold for withholding life-saving funding.

The concerns about thimerosal are even less defensible. The claim that thimerosal in vaccines is neurotoxic has been repeatedly and conclusively refuted across multiple large epidemiologic studies. This is settled science. More importantly, in many settings, thimerosal is essential in allowing multi-dose vaccine vials to remain safe and usable in environments where cold-chain reliability is inconsistent. Removing it without providing viable alternatives is functionally equivalent to reducing access.

The timing of this funding freeze is particularly concerning. The U.S has already stepped back from global health leadership, including moves to withdraw from the World Health Organization (WHO) and the dismantling of major components of the U.S. Agency for International Development (USAID). The consequences are dire, and estimates suggest these cuts will result in hundreds of thousands of additional deaths annually. Disruptions to HIV treatment programs, malaria prevention efforts, maternal health services, and nutrition support are already being reported across multiple regions. Health systems are still struggling to absorb these shocks.

Meanwhile, vaccination programs do not operate in isolation. Weakening them on top of these disruptions compounds risk and will turn already fragile systems into failing ones and localized health threats into broader regional instability.

Beyond routine childhood immunization, Gavi is also a central actor in global outbreak response. As a co-lead of the COVAX facility (alongside WHO, the Coalition for Epidemic Preparedness Innovations, and UNICEF), it helped finance procurement and coordinate the delivery of COVID-19 vaccines to low- and middle-income countries that would otherwise have been excluded from the market. It has supported the stockpiling and deployment of vaccines for high-consequence pathogens such as Ebola and maintains financing mechanisms that accelerate the development and equitable rollout of new vaccines. Withdrawing funding from Gavi will hamper the ability of the many countries that rely on its support to rapidly respond to outbreaks of diseases like Ebola. This leaves us all less prepared for the next pandemic.

It may be tempting to accept HHS Secretary Robert F. Kennedy Jr.’s framing of this as a bureaucratic dispute over accountability or product safety. It is not. It is a policy decision that introduces doubt into one of the most evidence-based interventions in medicine and delays the flow of resources needed to sustain it. Crucially, no viable alternative has been proposed. In the U.S., when thimerosal-containing influenza vaccines were phased out, several alternative formulations were readily available. That substitution is not feasible in many low-resource settings, where cost, storage, and distribution constraints fundamentally shape what is possible.

Gavi is not perfect. No multilateral institution is. But its core function of expanding access to life-saving vaccines rests on one of the strongest evidence bases in global health. Withholding funding in the absence of a credible, evidence-based alternative will reduce vaccine access, reverse hard-won progress, and increase the burden of preventable disease in populations that are already under strain.

Federal leaders must also remember that this will have consequences at home: infectious diseases do not respect borders. Weakening vaccination programs abroad does not make Americans safer; it increases the probability of outbreaks that are more difficult and more expensive to control once they spread. Continued U.S. support for Gavi is one of the most efficient tools available to prevent avoidable illness, stabilize vulnerable health systems, and reduce the likelihood that emerging threats reach our own communities. Walking away from that strategy is not fiscally prudent or scientifically justified; it is another preventable public health mistake.

Please enable JavaScript to view the comments powered by Disqus.